The objective of this experiment was to determine if increasing lysine in the diets of immunologically castrated (IC) male pigs would increase percentage fat free lean and carcass cutting yields when compared with physical castrates. The anti-gonadotropin-releasing factor (GnRF) immunological product (Improvest, Pfizer Animal Health) is used worldwide to immunologically castrate entire male pigs to control boar taint and take advantage of the inherent ability of the entire male to deposit more muscle, less fat, and grow more efficiently than physically castrated males. The immunization process essentially allows the pig to grow as an entire male pig for most of its life and then removes any boar odor (boar taint) before slaughter. Reported lean meat advantages may also provide economic benefits to the domestic meat industry. Approximately 1,200 male pigs [physical castrates, IC males, and entire males] were each assigned to 1 of 4 diet programs which differed in lysine content. In each case, lysine was fed in a conventional step-down program that culminated with the following concentrations in the late finishing diet: physical castrates fed low lysine (0.7%), IC fed low lysine (0.7%), IC fed low/medium lysine (0.8%), IC fed medium/high lysine (0.9%), IC fed high lysine (1.0%), and entire males fed high lysine (1.0%). At 25 wk of age (5 wk post-second injection), pigs were individually weighed and the 2 pigs (n=96) in each pen closest to the median pig BW were selected and slaughtered. The right side of each carcass was dissected into soft tissue, skin, and bone. Proximate composition was determined on the soft tissue to determine percentage fat-free lean. The left side of each carcass was weighed and initially fabricated into ham, loin, belly, and whole shoulder. Each primal piece was weighed again and further fabricated into respective subprimal cuts. Immunological castration did not change (P>0.05) shear force values or ultimate pH when compared with either physical castrates or entire males. Marbling appeared to decrease as dietary lysine was increased among IC males. As expected, IC males had a greater (P<0.05) percentage fat-free lean than physical castrates but less (P<0.05) than entire males. Immunologically castrated males fed diets with medium/high and high lysine had greater (P<0.05) lean cutting yields and carcass cutting yields than physical castrates. Lean cutting yield and carcass cutting yields appeared to increase as dietary lysine was increased among IC males. Overall, immunological castration improved carcass cutability, increased percentage fat free lean, and had no effect on pork quality when compared with physical castrates.

Body weights of finishing pigs can be variable within a finishing barn near the time of slaughter; therefore, it is common to market pigs over a period of time. This allows lighter pigs more time to gain BW and approach a desired end point. Use of immunological castration late in life to control boar taint, as an alternative to physical castration early in life, increases cutting yields of finishing male pigs compared with physical castrates. Because of common marketing strategies, it is important for advantages in cutting yields to span a broad spectrum of slaughter ages and BW. The primary objectives in this study were to evaluate carcass cutting yields, pork quality, belly quality, and bacon processing characteristics of immunologically castrated (IC) male pigs fed a moderate level of distillers dried grains with solubles and slaughtered at either 4 wk (early slaughter group) or 6 wk (late slaughter group) post-second injection. A total of 156 male pigs (physical castrates or IC males) were selected from a population of 1,200 finishing pigs. Data were analyzed with the MIXED procedure of SAS as a split-split plot design. Body weights of IC males were 3.60 kg heavier (P = 0.03) than physical castrates when slaughtered at 4 wk post-second injection and 7.52 kg heavier (P < 0.0001) than physical castrates when slaughtered at 6 wk post-second injection. Because of a lack of interaction (P > 0.05) between sex and time of slaughter post-second injection, some response variables were pooled. Hot carcass weights were not different (P = 0.57) between physical castrates (91.98 kg) and IC males (92.52 kg). There was a 2.77 percentage unit decrease (P < 0.001) in dressing percentage of IC males (71.78%) compared with physical castrates (74.55%). Lean cutting yields of IC males were 2.62 percentage units greater (P < 0.0001) than physical castrates and carcass cutting yields were 2.27 percentage units greater (P < 0.0001) for IC males when compared with physical castrates. There were no differences between IC males and physical castrates for shear force (P = 0.09), ultimate pH (P = 0.57), objective color (P ≥ 0.31), subjective color score (P = 0.64), or drip loss (P = 0.30). Bellies from IC males were thinner (P = 0.01) and had narrower belly flops (P < 0.0001) than bellies from physical castrates. There were no differences (P = 0.74) in cured belly cooked yield between IC males and physical castrates. Overall, immunological castration improved cutting yields, did not affect pork quality, made fresh bellies thinner, and did not affect cured belly characteristics when pigs were fed a moderate level of distillers dried grains with solubles during the finishing phase of production.

The objective of this experiment was to determine if increasing lysine in the diets of immunologically castrated (IC) male pigs would affect further processed product characteristics when compared with physical castrates or entire males. Raw materials for this experiment were derived from a previous experiment evaluating carcass characteristics. Physical castrates, IC males, and entire males were assigned to 1 of 4 diet programs with increasing lysine in a step-down lysine inclusion program that culminated with the following concentrations in the late finishing diet: physical castrate with low lysine (0.7%), IC with low lysine (0.7%), IC with low/medium lysine (0.8%), IC with medium/high lysine (0.9%), IC with high lysine (1.0%), and entire with high lysine (1.0%). Bellies were injected with a cure solution to a target of 110% of original green weight, and weighed again to determine brine uptake. Hams were injected with same cure solution to a target of 130% of green weight. Cure solution was formulated for a finished product inclusion of 1.5% salt, 0.34% phosphate, 0.05% sodium erythorbate, 0.11% sugar, and 0.014% sodium nitrate. Physical castrates had thicker (3.77 cm) bellies (P<0.05) than all treatment groups, except IC males fed low/medium lysine (3.73 cm). Entire males (2.85 cm) had the thinnest (P<0.05) bellies of all treatment groups. There were no differences (P>0.05) in percentage brine uptake for cured bellies among IC males regardless of dietary lysine (range 9.93 to 10.67%). Cooked yield of cured bellies was not different (P>0.05) among physical castrates or IC males regardless of lysine inclusion. Cooked yield of cured bellies from entire males (95.12%) was less (P<0.05) than cooked yield for any other treatment group. Pumped weight differences of cured hams among treatment groups were similar to green weight differences, and there were no differences (P>0.05) among any treatment groups for pump uptake percentage. There were also no differences in cook loss percentages among any treatment group. Therefore, differences in cooked yield are a reflection of initial green weight. There were no differences (P>0.05) for protein fat-free values among any treatment groups. Therefore, it can be concluded, in this population of pigs, there were no differences in further processed product characteristics among physical castrates and IC males.

The dose response of melengestrol acetate (MGA) on ADG (kg/d) and gain efficiency (gain/DMI, g/kg) was estimated in beef steers fed a finishing diet under commercial feedlot conditions. Melengestrol acetate is not approved for use in steers as a feed additive. The study design was five blocks of four pens (each pen was assigned a dose of MGA) with 166 to 200 steers per pen. Melengestrol acetate was fed to steers at 0 (n = 899, five pens), 0.1 (n = 900, five pens), 0.2 (n = 899, five pens), and 0.4 (n = 900, five pens) mg of MGA/steer daily. Pens within a block were slaughtered on the same day. Blocks 1 through 5 were fed MGA for 123, 122, 116, 124, and 138 d, respectively. The experimental unit was a pen of steers, and blocking was based on source of steers. The ADG was 1.81, 1.85, 1.80, and 1.83 kg/d for steers fed 0, 0.1, 0.2, and 0.4 mg MGA per day, respectively. For ADG, the dose was significant, but neither linear nor quadratic effects were significant. Compared with steers of the control group, ADG was greater for steers fed 0.1 mg MGA (P < 0.01). Feed efficiencies were 170, 173, 171, and 172 g/kg for steers fed 0, 0.1, 0.2, and 0.4 mg MGA/d, respectively; however, no effects of dose (P = 0.19) or linear (P = 0.21) or quadratic (P > 0.60) effects were observed. There was no evidence for either positive or negative effects of MGA on DMI, hot carcass weight, dressing percent, quality grade, yield grade, back fat thickness, marbling score, longissimus muscle area, and incidence of dark cutter carcasses in response to feeding MGA to steers at doses of 0.1, 0.2, and 0.4 mg daily. The incidence of buller behavior (0.43 to 1.11%) was low and did not permit an accurate test of the clinical observations that feeding MGA to steers decreases the occurrence of buller steers. Melengestrol acetate fed to finishing beef steers produced small improvements in growth performance (ADG, 2.2%) at the 0.1 mg MGA dose, but none of the doses examined produced improvement in carcass quality or yield grade measurements.

The objectives of the current study were to evaluate the efficacy and field safety of GnRH HCl administered at 3 doses in fixed-time artificial insemination (FTAI) programs (Ovsynch) in dairy cows. A common protocol was conducted at 6 commercial dairies. Between 188 and 195 cows were enrolled at each site (total enrolled = 1,142). Cows had body condition scores ≥ 2 and ≤ 4, were between 32 to 140 d in milk, and were clinically healthy. Within pen and enrollment day (enrollment cohort), cows were assigned randomly in blocks of 4 to each of 4 treatments: (1) 25mg of PGF2α on d 7 with FTAI 72 ± 2 h later (control); (2) 100 μg of GnRH on d 0, d 7 a dose of 25mg of PGF2α, and the second administration of 100 μg of GnRH (T100) administered either at 48 ± 2 h (d 9) after PGF2α with FTAI 24 ± 2 h later or 56 ± 2 h (d 9) after PGF2α and FTAI 17 ± 2 h later; (3) same as T100 with both injections of 150 μg of GnRH (T150); and (4) same as T100 with both injections of 200 μg of GnRH (T200). Three sites selected the first option and 3 sites selected the second option for the timing of the second injection of all doses of GnRH. Cows were observed daily for signs of estrus and adverse clinical signs. Cows not returning to estrus had pregnancy diagnosis between 42 and 65 d following FTAI. Pregnancies per FTAI (P/FTAI) were analyzed as a binary variable (1 = pregnant, 0 = not pregnant) using a generalized linear mixed model with a binomial error distribution and a logit link function. The statistical model included fixed effects for treatment, random effects of site, site by treatment, enrollment cohort within site, and residual. Parity (first vs. second or greater) was included as a covariate. For demonstration of effectiveness, α=0.05 and a 2-tailed test were used. Fifty-two cows were removed from the study because of either deviation from the protocol, injury, illness, culling, or death. Among the remaining 1,090 cows, 33.9% were primiparous and 66.1% were multiparous. Back-transformed least squares means for P/FTAI were 17.1, 27.3, 29.1, and 32.2% for control, T100, T150 and T200, respectively. The P/FTAI for each GnRH dose differed from that of the control. No differences were detected in P/FTAI between GnRH doses. No treatment-related adverse events were observed. Mastitis was the most frequently observed adverse clinical sign, followed by lameness and pneumonia. This study documents the efficacy and safety of doses of 100 to 200 μg of GnRH as the HCl salt when used in Ovsynch programs.